Valproic acid overcomes hypoxia-induced resistance to apoptosis

Oncology Reports

Volumn 27, Issue 4, 2012, Pages 1219-1226

  Cipro, Šimon ^a   Hřebačková, Jana ^a   Hraběta, Jan ^a   Poljaková, Jitka ^a   Eckschlager, Tomáš ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Apoptosis; Hypoxia; Neuroblastoma; Valproic acid

Indexed keywords

CASPASE 3; CASPASE 3 INHIBITOR; CISPLATIN; OXYGEN; PROTEIN BID; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL HYPOXIA; CELL LEVEL; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MITOCHONDRIAL RESPIRATION; MONOTHERAPY; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASPASE 8; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IN SITU NICK-END LABELING; NEUROBLASTOMA; TIME FACTORS; VALPROIC ACID;

EID: 84856573900     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1577     Document Type: Article

References (44)

1. Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216, 2003.
2. Furchert SE, Lanvers-Kaminsky C, Juurgens H, Jung M, Loidl A and Frühwald MC: Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 120: 1787-1794, 2007. (Pubitemid 46399367)
3. Mossman D and Scott RJ: Long term transcriptional reactivation of epigenetically silenced genes in colorectal cancer cells requires DNA hypomethylation and histone acetylation. PloS One 6: e23127, 2011.
4. Santini V, Gozzini A and Ferrari G: Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 8: 383-393, 2007.
5. Bokelmann I and Mahlknecht U: Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Mol Med 14: 20-27, 2007.
6. Fullgrabe J, Hajji N and Joseph B: Cracking the death code: apoptosis-related histone modifications. Cell Death Differ 1: 1238-1243, 2010.
7. Hrebackova J, Poljakova J, Eckschlager T, et al: Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells. Interdiscip Toxicol 2: 205-210, 2009.
8. Cinatl J, Scholz M, Driever PH, et al: Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 7: 766-773, 1996. (Pubitemid 26388767)
9. Michaelis M, Suhan T, Cinatl J, Driever PH and Cinatl J: Valproic acid and interferon-α synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int J Oncol 25: 1795-1799, 2004.
10. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
11. Vaupel P, Kallinowski F and Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465, 1989. (Pubitemid 20008770)
12. Hussein D, Estlin EJ, Dive C and Makin GW: Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther 5: 2241-2250, 2006. (Pubitemid 44530461)
13. Lara PC, Lloret M, Clavo B, et al: Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression. Radiat Oncol 4: 29, 2009.
14. Song X, Liu X, Chi W, et al: Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 58: 776-784, 2006. (Pubitemid 44351258)
15. Giuntoli S, Rovida E, Barbetti V, Cipolleschi MG, Olivotto M and Dello Sbarba P: Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations. Leukemia 20: 1291-1293, 2006. (Pubitemid 43905834)
16. Huang LE, Bindra RS, Glazer PM and Harris AL: Hypoxia-induced genetic instability - a calculated mechanism underlying tumor progression. J Mol Med (Berl) 85: 139-148, 2007. (Pubitemid 46188219)
17. Brizel DM, Scully SP, Harrelson JM, et al: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56: 941-943, 1996. (Pubitemid 26065381)
18. Hockel M, Schlenger K, Aral B, et al: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56: 4509-4515, 1996. (Pubitemid 26330463)
19. Hockel M, Schlenger K, Hockel S and Vaupel P: Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 59: 4525-4528, 1999. (Pubitemid 29428951)
20. Bossy-Wetzel E and Green DR: Detection of apoptosis by annexin V labeling. Methods Enzymol 322: 15-18, 2000. (Pubitemid 30482040)
21. Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36, 2002.
22. Yin X-M: Bid, a BH3-only multi-functional molecule, is at the cross road of life and death. Gene 369: 7-19, 2006.
23. Baek JH, Jang JE, Kang CM, Chung HY, Kim ND and Kim KW: Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 19: 4621-4631, 2000.
24. Liu X-H, Yu EZ, Li Y-Y and Kagan E: HIF-1alpha has an anti-apoptotic effect in human airway epithelium that is mediated via Mcl-1 gene expression. J Cell Biochem 97: 755-765, 2006.
25. Lee J-W, Bae S-H, Jeong J-W, Kim S-H and Kim K-W: Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med 36: 1-12, 2004. (Pubitemid 38379631)
26. Semenza GL: HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88: 1474-1480, 2000.
27. Shannon AM, Bouchier-Hayes DJ, Condron CM and Toomey D: Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29: 297-307, 2003. (Pubitemid 37069660)
28. Um JH, Kang CHD, Bae JH, et al: Association of DNA-dependent protein kinase with hypoxia inducible factor-1 and its implication in resistance to anticancer drugs in hypoxic tumor cells. Exp Mol Med 36: 233-242, 2004. (Pubitemid 38981420)
29. Graeber TG, Osmanian C, Jacks T, et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91, 1996. (Pubitemid 26008141)
30. Liu L, Ning X, Sun L, et al: Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 99: 121-128, 2008. (Pubitemid 350239040)
31. Piret J-P, Mottet D, Raes M and Michielis C: Is HIF-1alpha a pro- or an anti-apoptotic protein? Biochem Pharmacol 64: 889-892, 2002.
32. Suzuki H, Tomida a and Tsuruo T: Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 20: 5779-5788, 2001. (Pubitemid 32937947)
33. Kim SH, Jeong JW, Park JA, et al: Regulation of the HIF-1á stability by histone deacetylases. Oncol Rep 17: 647-651, 2007.
34. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV and Neckers LM: Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392: 405-408, 1998.
35. Sendoel A, Kohler I, Fellmann C, Lowe WS and Hengartner OM: HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase. Nature 465: 577-585, 2010.
36. Nardinocchi L, Puca R and Orazi GD: HIF-1á antagonizes p53-mediated apoptosis by triggering HIPK2 degradation. Aging 3: 33-43, 2011.
37. Flamant L, Notte A, Ninane N, Raes M and Michiels C: Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol Cancer 9: 191, 2010.
38. Dong Z, Venkatachalam Ma, Wang J, et al: Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms. J Biol Chem 276: 18702-18709, 2001.
39. Piret J-P, Cosse J-P, Ninane N, Raes M and Michiels C: Hypoxia protects HepG2 cells against etoposide-induced apoptosis via a HIF-1-independent pathway. Exp Cell Res 312: 2908-2920, 2006.
40. Chen G, Yuan PX, Jiang YM, Huang LD and Manji HK: Valproate robustly enhances AP-1 mediated gene expression. Brain Res Mol Brain Res 64: 52-58, 1999. (Pubitemid 29049235)
41. Hrebackova J, Hrabeta J and Eckschlager T: Valproic acid in the complex therapy of malignant tumors. Curr Drug Targets 11: 361-379, 2010.
42. Catalano MG, Fortunati N, Pugliese M, et al: Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 90: 1383-1389, 2005. (Pubitemid 40463993)
43. Nebbioso A Clarke N, Voltz E, et al: Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11: 77-84, 2005. (Pubitemid 40215841)
44. Muhlethaler-Mottet A, Meier R, Flahaut M, et al: Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol Cancer 7: 55, 2008.